Effectiveness of Nasal Sumatriptan in 5‐ to 12‐Year‐Old Children

Hershey, Andrew D.; Powers, Scott W.; LeCates, Susan L.; Bentti, Anna‐Liisa

doi:10.1046/j.1526-4610.2001.041007693.x

Cited by 40 publications

(30 citation statements)

References 7 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…in 10 children unresponsive to oral medications, ages 5 -12 years, and treating 57 headaches, reduction of headache severity was demonstrated with sumatriptan 20 mg within 45 min. Sumatriptan was well tolerated, with bad taste being the most frequent complaint [59]. A second study of 14 children under 10 years of age showed a statistically significant response to sumatriptan nasal spray 20 mg for both pain relief (p = 0.03) and pain-free status (p = 0.016) [60].…”

Section: Efficacy In Adolescents and Childrenmentioning

confidence: 99%

Sumatriptan: update and review

Cady

Schreiber

2006

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Sumatriptan is the first of a novel class of medications referred to as triptans. Since its approval for migraine in the 1990s, six other triptan products have received FDA approval. Despite the proliferation of triptans, sumatriptan remains the most frequently prescribed product in this therapeutic class. Sumatriptan has been instrumental in defining a biological basis for migraine. It is effective in treating migraine with or without aura, well tolerated and, when properly prescribed, safe. Sumatriptan injection is the only member of the triptan class approved for treatment of cluster headache. Studies with sumatriptan have also advanced the therapeutic intervention paradigm that permits patients to treat earlier and avoid substantial disability. Numerous pharmacoeconomic studies have demonstrated that sumatriptan decreases work loss productivity and improves quality of life.

show abstract

Section: Efficacy In Adolescents and Childrenmentioning

confidence: 99%

Sumatriptan: update and review

Cady

Schreiber

2006

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Although the Table II. Nasal sumatriptan data in the pediatric population [12][13][14][15][16][17][18][19] primary endpoints were not met in both of the above studies, [12,13] secondary endpoints showed efficacy for reducing migraine pain and symptoms, and outcomes were similar to those in adult trials.…”

Section: Nasal Sumatriptanmentioning

confidence: 93%

“…[12][13][14][15][16][17][18][19] One study randomized adolescents to sumatriptan 5, 10, or 20 mg nasal spray or placebo for treatment of a single migraine attack. [12] Fifteen percent of the 510 adolescents (12-17 years of age) in the trial used migraine prophylaxis medication.…”

Section: Nasal Sumatriptanmentioning

confidence: 99%

The Use of Triptans for Pediatric Migraines

Eiland

Hunt

2010

Pediatric Drugs

View full text Add to dashboard Cite

Migraine headaches frequently occur in the pediatric population, with a prevalence of 3% in children 2-7 years of age, 4-11% in children 7-11 years of age, and 8-23% in children 11 years of age and older. Migraine without aura is more than twice as common as migraine with aura in children. Headaches are the third leading cause of emergency room referrals and rank in the top five health problems of children. The 2004 American Academy of Neurology's treatment parameter for migraine in children and adolescents recommended that nasal sumatriptan be considered for acute treatment; however, data were lacking to make a decision regarding the available oral triptans at that time. The more recently released European guidelines discuss three different triptans for use in children but no specific triptan was recommended. Currently, six of the seven available triptans have been studied for efficacy and safety in the pediatric population; however, only a few well controlled clinical studies have been conducted. Sumatriptan has the most available data on outcomes in general, with nasal sumatriptan showing the most positive results. Nasal sumatriptan is approved in children older than 12 years of age in Europe. Oral sumatriptan does not show any clinical benefit versus placebo in children. Rizatriptan and zolmitriptan have conflicting efficacy and safety data, with most studies favoring the use of oral rizatriptan and nasal zolmitriptan. Almotriptan is the first triptan to obtain a US FDA indication in adolescents with migraines lasting 4 or more hours. This approval was based upon two studies, one large clinical trial and one very small, open-label, pilot study. At this time, there are insufficient data to recommend naratriptan and eletriptan for first- or second-line use in pediatric patients with migraines. There are currently no efficacy data for frovatriptan in pediatric patients, which limits its use in this population. Adverse effects of triptans and pharmacokinetic data in children and adolescents are similar to those in adults. The triptan class should be considered as an acute treatment option for children and adolescents with migraines, although their use is mostly 'off-label'. Of the available triptans, there are more positive efficacy data for sumatriptan and zolmitriptan nasal sprays, and rizatriptan and almotriptan tablets than for the other triptans.

show abstract

“…Informed consent was obtained from the guardians in the presence of the patient. All guardians were told about the non-FDA indications of all triptans including the references in the literature supporting triptan efficacy and safety in the abortive treatment of migraine in patients aged less than 18 [3][4][5][6][7]. Severity of pain and duration of the attacks were recorded.…”

Section: Methodsmentioning

confidence: 99%

Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open–label pilot study of efficacy and safety

Charles

2006

J Headache Pain

View full text Add to dashboard Cite

The objective was to investigate the safety and efficacy of almotriptan in patients aged 11–17 years old with acute migraine. Fifteen patients aged 11–17 with a history of migraine with or without aura were treated with almotriptan. Reduction in headache severity, disability and adverse effects were studied. Almotriptan in doses ranging from 6.25 to 12.5 mg was well tolerated. There were virtually no adverse effects except for one case of transient mild stiffness. Of the 15 patients, only 2 demonstrated no efficacy without adverse effects. In the other 13 patients, not only was almotriptan effective, but again, no significant adverse effects were reported. Almotriptan is probably safe and effective in patients aged 11–17. This small open–label pilot study should support the feasibility of a large randomised controlled study to demonstrate tolerability and efficacy of almotriptan in children and adolescents with episodic migraine.

show abstract

Effectiveness of Nasal Sumatriptan in 5‐ to 12‐Year‐Old Children

Cited by 40 publications

References 7 publications

Sumatriptan: update and review

Sumatriptan: update and review

The Use of Triptans for Pediatric Migraines

Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open–label pilot study of efficacy and safety

Contact Info

Product

Resources

About